Double GnRH-antagonist dose before HCG administration may prevent OHSS in oocyte-donor cycles: A pilot study

Reproductive BioMedicine Online

Volumn 21, Issue 2, 2010, Pages 159-165

  Prapas, Yannis ^a,b   Panagiotidis, Ioannis ^a   Kalogiannidis, Ioannis ^a,b   Gjata, Elinda ^a   Papatheodorou, Achileas ^a   Prapa, Stella ^a   Kasapi, Lia ^a   Goudakou, Maria ^a   Prapas, Nikos ^a,b  

^a IANENTRO Fertility Center   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

GnRH antagonists; IVF ICSI; OHSS; oocyte donors; ovarian stimulation

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; ESTRADIOL VALERATE; GANIRELIX; GONADORELIN ANTAGONIST; PROGESTERONE; RECOMBINANT FOLLITROPIN; TRIPTORELIN;

ADD ON THERAPY; ADULT; ARTICLE; CONTROLLED STUDY; DONOR; DRUG WITHDRAWAL; EMBRYO; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLICLE CYST; FOLLITROPIN RELEASE; HUMAN; MAJOR CLINICAL STUDY; OOCYTE; OOCYTE DONATION; OOCYTE RETRIEVAL; OVARY HYPERSTIMULATION; PILOT STUDY;

ADULT; CHORIONIC GONADOTROPIN; ESTRADIOL; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; OVARIAN HYPERSTIMULATION SYNDROME; PILOT PROJECTS; TISSUE DONORS;

EID: 78650204484     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rbmo.2010.04.030     Document Type: Article

References (39)

1. M. Aboulghar Prediction of ovarian stimulation syndrome (OHSS). Estradiol levels has an important role in the prediction of OHSS Hum. Reprod. 18 2003 1140 1141
2. M. Aboulghar A prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS Rep. Biol. Med. Online 15 2007 271 279
3. B. Asimakopoulos, N. Nikolettos, and B. Nehls Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures Fertil. Steril. 86 2006 636 641
4. B. Ata, A. Seyhan, and S. Orhaner High dose cabergoline in management of ovarian hyperstimulation syndrome Fertil. Steril. 92 2009 1168.e1 1168.e4
5. D. Bodri, J.J. Guillen, and A. Galindo Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin- releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study Fertil. Steril. 2 2009 365 371
6. C.A. Dahl Lyons, C.A. Wheeler, and G.N. Frishman Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors Hum. Reprod. 9 1994 792 799
7. D. De Jong, N.S. Macklon, and B.M. Mannaerts High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization Hum. Reprod. 13 1998 573 575
8. A. Delvigne, and S. Rozenberg Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review of the literature Hum. Reprod. Update 8 2002 559 577 (Pubitemid 35452781)
9. P.E. Egbase, M. Al Sharhan, and P. Berlingieri Serum estradiol and progesterone concentrations during prolonged coasting in 15 women at risk of ovarian hyperstimulation syndrome following ovarian stimulation for assisted reproduction treatment Hum. Reprod. 15 2000 2082 2086
10. ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risk related to polycystic ovary syndrome Fertil. Steril. 81 2004 19 25
11. B.E. Friden, and L. Nilsson Gonadotrophin-releasing hormone-antagonist luteolysis during the preceding mid-luteal phase is a feasible protocol in ovarian hyperstimulation before in vitro fertilization Acta Obstet. Gynecol. Scand. 84 2005 812 816
12. The Ganirelix Dose-Finding Study Group A double-blind, randomized, does-finding study to assess the efficacy of the gonadotropin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinization hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone Hum. Reprod. 13 1998 3023 3031
13. J.A. Garcia-Velasco, V. Isaza, and G. Quea Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing Fertil. Steril. 85 2006 547 554
14. J.A. Garcia-Velasco, A. Zuniga, and A. Pacheco Coasting acts through down regulation of VEGF gene expression and protein secretion Hum. Reprod. 19 2004 1530 1538
15. J. Giles, A. Requena, and J. Garcia-Velasco GnRH analogue for the prevention of ovarian hyperstimulation syndrome: a pilot study Fertil. Steril. 4 2009 1366 1369
16. R.L. Gustofson, F.W. Larsen, and M.R. Bush Treatment with gonadotropin-releasing hormone (GnRH) antagonists in women suppressed with GnRH agonist may avoid cycle cancellation in patients at risk for ovarian hyperstimulation syndrome Fertil. Steril. 85 2006 251 254
17. R.L. Gustofson, J.H. Segars, and F.W. Larsen Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome Hum. Reprod. 21 2006 2830 2837
18. E. Hernandez, and J.L. Gomez-Palomares No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles Fertil. Steril. 91 2009 1358 1361
19. J. Itskovitz, R. Boldes, and J. Levron Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist Fertil. Steril. 56 1991 213 220
20. T. Lainas, G. Petsas, and G. Stavropoulou Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization Fertil. Steril. 78 2002 529 533
21. T.G. Lainas, I.A. Sfontouris, and I.Z. Zorzovillis Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist Rep. Biol. Med. Online 15 2007 408 412
22. T.G. Lainas, I.A. Sfontouris, and I.Z. Zorzovillis Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol Rep. Biol. Med. Online 18 2008 15 20
23. R.D. Meldrum Vascular endothelial growth factor, polycystic ovary syndrome, and ovarian hyperstimulation syndrome Fertil. Steril. 78 2002 1170 1171
24. R. Michaelson-Choen, C. Altarescu, U. Beller, R. Reens, T. Halevy-Shalem, and T. Eldar-Geva Does elevated human chorionic gonadotropin alone trigger spontaneous ovarian hyperstimulation syndrome? Fertil. Steril. 90 2008 1869 1874
25. D. Minaretzis, M.M. Alper, and S.P. Oskowityz Gonadotropin releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells Am. J. Obstet. Gynecol. 172 1995 1518 1525
26. F. Olivennes, J.S. Cunha-Filho, and R. Franchin The use of GnRH antagonists in ovarian stimulation Hum. Reprod. Update 8 2002 279 290
27. E.G. Papanicolaou, C. Pozzobon, and E.M. Kolibianakis Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in-vitro fertilization cycles Fertil. Steril. 85 2006 112 120
28. Y. Prapas, N. Prapas, and A. Hatziparasidou The echo guided embryo transfer maximizes the IVF results Acta Eur. Fertil. 26 1995 113 115
29. Y. Prapas, N. Prapas, and A. Hatziparasidou Ultrasound-guided embryo transfer maximizes the IVF results on day 3 and day 4 embryo transfer but has no impact on day 5 Hum. Reprod. 16 2001 1904 1908
30. Y. Prapas, N. Prapas, and E.E. Jones The window for embryo transfer in oocyte donation cycles depends on the duration of progesterone treatment Hum. Reprod. 13 1998 720 723
31. Y. Prapas, N. Prapas, and Y. Panagiotidis Cervical dilatation has a positive impact on the outcome of IVF in randomly assigned cases having two previous difficult embryo transfers Hum. Reprod. 19 2004 1791 1795
32. B. Rizk, and J. Smitz Ovarian hyperstimulation syndrome after super-ovulation using GnRH agonists for IVF and related procedures Hum. Reprod. 7 1992 320 327
33. G.I. Serour, M. Aboulghar, and R. Mansour Complications of medically assisted conception in 3500 cycles Fertil. Steril. 4 1998 638 642
34. D.B. Shapiro, D. Mitchell-Leef, and M. Carter Ganirelix acetate use in normal- and poor-prognosis patients and the impact of estradiol patterns Fertil. Steril. 83 2005 666 670
35. G. Sher, C. Zouves, and M. Feinman Prolonged coasting: an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization Hum. Reprod. 10 1995 3107 3109
36. Z. Shoham, M. Schachter, and E. Loumaye Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo-controlled study Fertil. Steril. 62 1994 137 142
37. S.R. Soares, R. Gomez, and C. Simon Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome Hum. Reprod. Update 14 2008 321 333
38. The Practice Committee of the American Society for Reproductive Medicine Ovarian hyperstimulation syndrome Fertil. Steril. 86 Suppl. 2006 S178 S183
39. E. Vrtacnik-Bokal, I. Virant Klun, and I. Verdenik Follicular estradiol and VEGF after GnRH antagonists or GnRH agonists in women with PCOS Rep. Biol. Med. Online 18 2008 21 28